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INTRODUCTION 
 
Globally, gastric cancer is one of the most common 
malignant cancers with serious consequences for 
population health and mortality. The 2020 Cancer 
Statistics Survey shows that the gastric cancer mortality 
rate is ~40% [1]. The development and use of 
gastroscopy has dramatically increased diagnosis and 
treatment, this is most effective in early stage disease 
[2–4], whereas most gastric cancer patients present in 
the latter stages of disease to the clinic. Gastric cancer is 
associated with significant secondary metastases which 
cannot be treated by conventional surgery [5]. The 
prognosis of advanced stage gastric cancer patients is 
low, with a typical survival period of 8-12 months [6–
8]. Gastric cancer tumor infiltration and metastasis are 
key causes of poor patient prognosis [9]. Mechanistic 
explanations of such effects include oncogene 
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Cancer development and progression can be regulated by the levels of endogenous factors. Gastric cancer is an 
aggressive disease state with poor patient prognosis, needing the development of new diagnostics and 
therapeutic strategies. We investigated the close association between follistatin-like 3 (FSTL3) and different 
cancers, and focused on its role in gastric cancer cell function. Using cancer bioinformatics, we found that FSTL3 
expression is elevated in a large majority of the 33 cancers we analyzed in publicly available cancer databases. 
Elevated levels of FSTL3 is associated with poor patient prognosis in gastric cancer. In a comparison of normal 
gastric epithelial cells and gastric cancer cell lines, FSTL3 expression was consistently elevated in gastric cancer 
cells. Overexpression of FSTL3 promoted gastric cancer cell viability, proliferation and migration. Conversely, 
FSTL3 knockdown inhibits these cellular processes. Using bioinformatics, we found that the FSTL3 mRNA has a 
potential binding site in the 3’-UTR for a small microRNA, miR-486-5p. Further bioinformatics revealed 
significant negative correlation between FSTL3 and miR-486-5p levels. Using luciferase reporter constructs, we 
provide evidence that the 3’UTR from the FSTL3 mRNA can confer downregulation in the presence of miR-486-
5p. These studies lead us to conclude that FSTL3 has oncogenic properties and increased expression of this gene 
product promotes gastric cancer development and progression. 
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activation, tumor suppressor inactivation, and abnormal 
cellular metabolism. The emergence of cancer 
bioinformatics has led to the rapid identification and 
validation of new cancer markers and prognostic 
indicators. For example, Pan and colleagues found that 
layilin (LAYN) is a new prognostic and immune 
infiltration marker in gastric cancer [10]. Aberrant 
expression of the homeobox-related transcription factor 
HOXC10 is also linked to gastric cancer cell migration, 
proliferation and tumor development [11]. The 
application of cancer bioinformatics is thus a powerful 
tool in identifying new gastric cancer biomarkers and 
therapeutic targets. 
 
The follistatin family of secreted glycoproteins includes 
follistatin-like 3 (FSTL3). More than 20 yrs ago, it was 
discovered that the FSTL3 locus undergoes 
chromosomal rearrangement linked to development of 
non-Hodgkin lymphoma [12]. Subsequent work has 
implicated FSTL3 in cellular differentiation, insulin 
resistance, aging, obesity and arteriosclerosis [13–16]. 
However, recent studies implicated FSTL3 in the 
regulation of a range of cancers. For example, FSTL3 
expression can be used to distinguish between benign 
and malignant breast cancer states [17]. Moreover, an 
FSTL3 antagonist inhibited breast cancer cell 
proliferation [18]. However, how FSTL3 regulates 
cancer development and progression is unclear; 
furthermore, very little is known about FSTL3 
regulation of gastric cancer. 
 
Non-coding RNAs (ncRNAs) usually do not encode 
protein but regulate protein translation and/or mRNA 
degradation [19]. Such ncRNAs include lncRNAs, 
microRNAs and circRNAs [20]. A microRNA 
(miRNA) is an endogenously expressed non-coding 
RNA 18-25 nucleotides in length, which frequently bind 
to the 3'-untranslated region (3’-UTR) of the target 
mRNA, causing degradation or a block in translation by 
ribosomes [21]. Abnormal miRNA expression can 
affect cancer development and progression by 
modulating cell proliferation, migration and invasion 
[22, 23]. The identification of new gastric cancer 
biomarkers associated with such features of cancer cell 
behavior could provide new opportunities for disease 
intervention. 
 
In this study, we used cancer bioinformatics to 
evaluate FSTL3 levels in different cancers in the 
TCGA database. Further analysis of FSTL3 levels in 
normal and tumor gastric tissues was analyzed to 
evaluate the potential role of FSTL3 as a gastric cancer 
biomarker. We then addressed the role of FSTL3 in 
gastric cancer using in vitro cellular models alongside 
in vivo animal models. Our studies now provide new 
insights into how abnormal control of FSTL3 
expression regulates gastric cancer development and 
progression. 
 




All patient data used for this analysis were derived from 
the public databases such as TCGA [24] (https://tcga-
data.nci.nih.gov/tcga/) and GEO (https://www.ncbi.nlm. 
nih.gov/). R software was used to analyze gene 
expression and perform functional gene enrichment. 
Moreover, using the visualization tools in StarBase [25] 
(https://web.archive.org/web/20110222111721/http://sta
rbase.sysu.edu.cn/), we were able to evaluate the link 
between miRNA levels and clinical cancer datasets in 
TCGA. The interaction properties between miRNA and 
mRNA were predicted using StarBase. Protein-protein 
interaction (PPI) studies was carried out using the 
STRING database [26] (https://string-db.org). 
Cytoscape (https://cytoscape.org/) with the MCODE 




Human gastric epithelial cell line GES1 and human 
gastric cancer cell lines BGC-823, MGC-803, SGC-
7901, AGS, and HGC-27 were purchased from the cell 
bank at the Chinese Academy of Sciences. MGC-803, 
SGC-7901, and HGC-27 cells were cultured in RPMI-
1640, AGS cells cultured in DMEM/F12 and the 
remaining cell lines cultured in DMEM (GIBCO, USA). 
All cells were cultured in medium supplemented with 
10% fetal bovine serum (GIBCO, USA), 100 μg/ml 
penicillin, and 100 μg/ml streptomycin and grown at 




HEK293T cell line were co-transfected with plasmids 
pLKO.1, pCDH (synthesized by Shanghai Gema 
Pharmaceutical Technology Co., Ltd.), VSVG, and 
GAG-POL using Lipofectamine 3000 (Invitrogen, 
USA), for the production of replication-defective 
lentiviral particles. Recombinant lentivirus was 
harvested at either 48 or 72 h after plasmid transfection. 
Cell medium was concentrated using PEG-8000 and 
virus titer determined. Viral particles were added to 
cultured cells and stable clones selected using 1 μg/ml 





All proteins were separated by SDS-PAGE and then 
electroblotted onto PVDF membranes (Millipore, USA) 
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before blocking with 5% (w/v) skimmed milk (BD, 
USA) for 1 h. The blocked PVDF membrane was 
incubated with diluted primary antibody in blocking 
buffer at 4° C overnight. The next day, the PVDF 
membrane was rinsed and incubated at room 
temperature with diluted HRP-conjugated secondary 
antibodies such as anti-mouse-HRP (Abcam, USA) or 
anti-rabbit-HRP (Abcam, USA) for 2 h. ECL 
luminescent solution (Meilunbio, China) was used to 
visualize bound antibodies using a digital gel imaging 
system (Biorad, USA). The antibodies used are: mouse 
anti-β-Actin used at 1:5000 (CST, USA; #4970S), 
FSTL3 used at 1:1000 (Abcam, USA; #ab232761). 
 
Dual-luciferase reporter assay 
 
Luc-3'-UTR of FSTL3 and mutant form were separately 
subcloned into the pmirGLO plasmid (Addgene, USA) 
to establish wt-FSTL3-luc (WT) and mut-FSTL3-luc 
(Mut) plasmid constructs respectively. The miRNA 
mimic, internal control, and parental luciferase plasmid 
were co-transfected into cells. Luciferase activity was 
assayed 48 h after transfection using the Dual-
Luciferase Reporter Assay System (Promega, USA). 
 
RNA isolation and qRT-PCR 
 
RNeasy Plus Universal Mini Kit (QIAGEN, USA) was 
used to isolate total RNA from cell lines, and HiScript® 
II 1
st
 Strand cDNA Synthesis Kit (Vazyme, China) was 
used to reverse transcribe into cRNA. At the same time, 
the miRNeasy Micro Kit (QIAGEN, USA) was used to 
isolate miRNA from cell lines, and the miRNA 1
st
 
Strand cDNA Synthesis Kit (Vazyme, China) was used 
for reverse transcription of miRNA. For the extracted 
RNA and miRNA, qRT-PCR was performed on the 
Bio-Rad CFX-96 (Biorad, USA) system using the 
SYBR Green (Yisen, USA) method to determine the 
relative RNA levels. β-actin and U6 mRNAs were used 
as endogenous controls. The primer sequences used to 
detect FSTL3 and Ki67 mRNAs are: FSTL3-F:  
5-GTGCCTCCGGCAACATTGA-3, FSTL3-R: 5-GCA 
CGAATCTTTGCAGGGA-3, Ki67-F:5-GGGCCAATC 
CTGTCGCTTAAT, Ki67-R:5-GTTATGCGCTTGCG 
AACCT-3. The synthesis of primers, plasmid 
sequencing, miRNA reverse transcription, sequencing, 
primer synthesis and FSTL3 siRNA synthesis were 
done commercially (Ribobio, China). 
 
RNA immunoprecipitation (RIP) 
 
RNA-protein-antibody complexes were captured 
using Protein A/G (ThermoFisher, USA). RNA was 
eluted by adding TRIzol directly to magnetic beads 
and isolated as per the manufacturer's instructions. 
cDNA was synthesized using HiScript® II 1
st
 Strand 
cDNA Synthesis Kit (Vazyme, China) and analyzed 
by qRT-PCR. 
 
Cell viability assay 
 
In a 96-well plate, 3×10
3
 cells in a 100 μl volume were 
added to each well; each group had 5 multiple wells. 
After allowing the cells to adhere, 10 μl of CCK-8 
solution (Dojindo, Japan) was added to each well. The 
96-well plate was incubated in an incubator for 1 h, and 
absorbance measured at 450 nm using a microplate 
reader (BioTek, USA). The assay was independently 
repeated three times. 
 
Cell migration and invasion assay 
 
A Transwell filter or chamber (Corning, USA) was used 
to analysis cell migration and invasion. 600 μl of cell 
suspension was added to the upper chamber, and the 
cells were suspended serum-free medium. Matrigel 
(BD, USA) was added to the upper chamber for 
invasion assay or 10% FBS added to the lower chamber 
for cell migration assay. 24 h after incubation, the cells 
that had migrated through the Transwell membrane 
filter were fixed with formalin (GBICO, USA) and 
stained with crystal violet. The number of migrated 
cells were imaged using an inverted microscope 
(Olympus, Japan) and fields of cells counted. At least 
five random fields of view were selected for each 
calculation, and all determinations were independently 
repeated three times. 
 
Wounded cell monolayer closure assay 
 
An in vitro wounded cell monolayer assay was also 
used to study cell migration. The cells were seeded in 6-
well plates (1 × 10
6
 per well), and after cell adhesion, 
linear scratch wounds were made in the cell monolayer 
using a sterile 200 µl plastic pipette tip. 
Photomicrographs were captured using a digital 
Olympus camera (Olympus, Japan) 48 h after treatment 
or stimulation. 
 
Human-mouse tumor xenograft model 
 
Animal experiments were conducted under the guidelines 
of the Laboratory Animal Center of Wuhan University of 
Science and Technology. BALB/c Nude mice, which 
were 4 weeks old and ~15 g weight per mouse were 
purchased from Beijing Huafukang Experimental Animal 
Co., Ltd., and housed in the Experimental Animal Center 
of Wuhan University of Science and Technology. Human 
gastric cancer cells were digested with trypsin (GIBCO, 
USA) without phenol red and EDTA, then resuspended 
in PBS containing 50% Matrigel (BD, USA). The cell 
suspension 2x10
6
 cells/ml was injected subcutaneously 
 
www.aging-us.com 20305 AGING 
into the dorsal side of the Nude mice. The mice were 
sacrificed 4 weeks later for biochemical and 
histopathological analyses were performed on the tumor 
samples. 
 
To study metastasis in vivo, 2×10
5
 cells of each group 
were re-suspended in 100 µl PBS, and intravenously 
injected into the tail vein of BALB/c nude mice (10 
mice/group). After 28 days, the number of mice with 
metastasis was counted. 
 
Histology and histochemistry 
 
The tissues were fixed, dehydrated, and paraffin-
embedded in the 10% formalin to make 5 µm tissue 
sections for hematoxylin-eosin staining, and 
observation using a digital microscope (Olympus, 
Japan). Xylene was used to dewax them twice for 15 
min each time. The tissue sections were incubated in 
3% (v/v) H2O2 (Sigma-Aldrich, St. Louis, MO, USA) 
at 37° C for 30 min, boiling in 0.01 M citric acid buffer 
at 95° C for 20 min, and then blocked with non-
specific serum solution at 37° C for 10 min before 
incubation with diluted primary antibodies at 37° C for 
2 h. Tissue sections were then incubated with species-
specific secondary antibodies conjugated to 
horseradish peroxidase (HRP) and counterstained with 
hematoxylin (Meilunbio, China) at room temperature 
for 4 min. The sections were observed using a digital 
microscope (Olympus, Japan). The following 
antibodies were used: rabbit anti-FSTL3 at 1:50 
(Abcam, USA; #ab232761). 
 
Cell adhesion assay 
 
In a 96-well plate with Matrigel (BD, USA) already 
spread. 2000 cells were seeded in each well, and serum-
free medium was used to cultivate the cells. After 2 h of 
incubation, cells adhered to Matrigel were washed twice 
with PBS. After fixation with 4% paraformaldehyde 
(Meilunbio, China) for 10 min, DAPI (Meilunbio, 
China) staining was used to observe the number of 
adherent cells under a fluorescence microscope 
(Olympus, Japan). Each experiment was repeated at 
least at least 3 times. 
 
Focal adhesion assay 
 
The experimental method is like immunofluorescence. 
The following antibodies were used: anti-F-actin 




Comparisons between groups and datasets were 
performed using R software version 4.0.3. Comparisons 
were completed using a one-way analysis of variance 
(ANOVA) and two-tailed Student's t-test. Correlations 
were calculated using the Pearson correlation. Kaplan–
Meier analyses were used to analyze cancer patient 
survival. All data are presented with error bars 
indicating mean ±SD. Statistical significance cutoff is at 
P<0.05. 
 
Availability of supporting data 
 
The data and files generated during this study are 




FSTL3 expression is associated with gastric cancer 
and poor patient prognosis 
 
FSTL3 expression was profiled in clinical datasets for 
33 cancers deposited in the TCGA database (Figure 
1A). FSTL3 expression was elevated, notably in CHOL, 
COAD, GBM, HNSC, KIRC, KIRP, READ, STAD and 
THCA cancers; however, FSTL3 expression was 
decreased in KICH, LUAD, LUSC, PCPG, UCEC 
cancers. To further analyze gastric cancer (stomach 
adenocarcinoma, STAD) increased FSTL3 expression 
(Figure 1A) we used the GEO clinical dataset 
GSE33335. This dataset contains gene profiling data 
from cancerous tissues and non-cancerous adjacent 
tissues taken from 25 gastric cancer patients. FSTL3 
expression was increased in gastric cancer compared to 
control tissues (Figure 1B). Next, we evaluated the 
clinical implications of FSTL3 expression in gastric 
cancer patient prognosis using Kaplan-Meier analysis 
(Figure 1C). The median FSTL3 expression in gastric 
cancer tissues was defined as the cut-off value. All 
STAD patients were divided into FSTL3 low expression 
and high expression groups (n=175). We found that the 
high FSTL3 expression caused decreased STAD patient 
survival over a 10 yr period, P=0.036 (Figure 1C). 
 
We also performed Univariate Cox analysis to analyze 
histopathological characteristics, age, gender, and 
disease staging (Table 1). FSTL3 expression was 
increased with older age and later stages of gastric 
cancer disease (Table 1). However, disease grade nor 
gender had no significant correlation with FSTL3 
expression (Table 1). Gastric cancer patients thus 
exhibit increased FSTL3 expression which influences 
disease progression and survival. 
 
Gene enrichment and functional analyses for 
elevated FSTL3 expression 
 
We screened for differentially expressed genes from the 
FSTL3 high and low expression groups in gastric cancer 
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(Figure 1C). We found 122 differentially expressed 
genes linked to the STAD database in TCGA and these 
are depicted as points on the gene expression log plot 
(Figure 2A). The top 10 differentially expressed genes 
linked to FSLT3 expression are shown in Figure 2B. 
These differentially expressed genes analyzed by gene 
ontology descriptors include extracellular matrix 
organization, extracellular structure organization, 
ossification, negative regulation of cellular responses to 
growth factor stimulus and collagen fibril organization 
(Figure 2C). The top five biochemical pathways 
identified by enrichment analysis using the Kyoto 
Encyclopedia of Gene and Genomes (KEGG) are focal 
adhesions, PI3K-Akt signal transduction, ECM-receptor 
interactions, protein digestion and absorption, and 
cancer proteoglycans (Figure 2D). These 122 
differentially expressed genes were imported into the 
STRING database to construct PPI networks. These 
genes can be linked into a singular network with 121 




Figure 1. Elevated FSTL3 expression in gastric cancer is linked to poor patient prognosis. (A) Profiling of FSTL3 expression in 33 
cancers within the TCGA database. (B) Analysis of FSTL3 expression in non-cancerous and cancerous gastric tissues using the GEO clinical 
dataset GSE33335. (C) Kaplan-Meier analysis of gastric cancer patient overall survival after classification into high (red) and low (blue) FSTL3 
expression groups (n=175). Significance indicated as follows: *P<0.05, **P<0.01, ***P<0.001. 
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Table 1. Univariate Cox analysis of gastric cancer patient clinical 
features linked to increased FSTL3 expression. 
 HR HR.95L HR.95H P-value 
age 1.026965748 1.007829689 1.046465151 0.00556017 
gender 1.483828302 0.979779065 2.247186647 0.062392212 
grade 1.367875492 0.946580494 1.976676441 0.095375967 
stage 1.535478376 1.221185829 1.930659353 0.000242497 
T 1.297541887 1.023344886 1.645207762 0.031516711 
M 2.048306027 1.096196896 3.827375896 0.024581693 
N 1.267206892 1.068895108 1.5023114 0.006386528 
Bold values are statistically significant (P<0.05). 
COL1A1, COL5A1, COL5A1 constitute the top five 
nodes. By using the MYOCD tool in Cytoscape, we 
identified core subnet modules within this PPI network; 
the top three nodes are depicted (Figure 2F). 
 
Elevated FSTL3 levels promote gastric cell 
proliferation and migration 
 
The expression of FSTL3 in a range of gastric cell lines 
was evaluated (Figure 3). Normal gastric epithelial cell 
line GES1 was compared to 5 different gastric cancer cell 
lines and Western blotting of cell lysates showed clear 
differences in FSTL3 protein levels (Figure 3A). FSTL3 
expression was lowest in control GES1 cell line; however, 
FSTL3 levels were raised in all gastric cancer cell lines 
with the highest expression in MGC-803 and lowest in 
SGC-7901 cell lines (Figure 3A). Further analysis of the 
endogenous FSTL3 mRNA levels using qRT-PCR further 
supported this trend, with SGC-7901 showing 1.5-fold 
rise compared to 4-fold rise in MGC-803 cells (Figure 
3B). These 2 lines were then selected as low and high 
FSTL3 expressors for testing FSTL3 regulation of gastric 
cancer cell function. In order to explore whether FSTL3 
regulates gastric cancer cell function, we overexpressed 
FSTL3 in SGC-7901 cells (Figure 3C). We showed that 
this FSTL3 plasmid caused 3-fold rise in FSTL3 mRNA 
levels; furthermore, this correlated with an increase in 
FSTL3 protein levels (Figure 3C). We then made a 
lentiviral system to express small hairpin RNAs 
(shRNAs) that target the FSTL3 mRNA; screening 3 
different FSTL3-specific shRNAs showed that sh-1 was 
most effective (Figure 3D). FSTL3 mRNA levels were 
reduced by 60% using sh-1; a similar knockdown in 
FSTL3 protein levels was also evident (Figure 3D). 
 
We then assessed FSLT3 overexpression or knockdown 
on gastric cancer cell responses (Figure 3E–3H). 
Measurement of cell viability showed increased FSTL3 
levels promoted gastric cancer cell line SGC-7901 
viability; in contrast, FSTL3 knockdown caused 
decreased cell viability in MGC-803 (Figure 3E). 
Measurement of new DNA synthesis using EdU 
incorporation showed 25% increased cell proliferation 
upon FSTL3 overexpression in gastric cancer cell line 
SGC-7901 (Figure 3F). Again, FSTL3 knockdown 
caused 25% decrease in MGC-803 cell proliferation 
(Figure 3F). We then asked whether FSTL3 
overexpression or knockdown affected cell monolayer 
closure, which is dependent on both cell proliferation 
and migration (Figure 3G). FSTL3 overexpression 
promoted a 20% increase in monolayer wound closure 
compared to control in gastric cancer cell line SGC-7901 
(Figure 3G). However, FSTL3 knockdown promoted a 
30% decrease in monolayer wound closure compared to 
control in gastric cancer cell line MGC-803 (Figure 3G). 
 
We also assessed FSTL3 overexpression or knockdown 
on cell migration using the Transwell assay (Figure 
3H). FSTL3 overexpression promoted a 2-fold increase 
in cell migration compared to control in gastric cancer 
cell line SGC-7901 (Figure 3H). However, FSTL3 
knockdown promoted a 60% decrease in cell migration 
compared to control in gastric cancer cell line MGC-
803 (Figure 3H). We also assessed FSTL3 to the 
formation of cell colonies in culture, an important 
feature of tumor growth (Figure 3I). FSTL3 knockdown 
caused 50% decrease in gastric cancer cell line MGC-
803 colony formation compared to control (Figure 3I). 
FSTL3 was also overexpressed in the normal gastric 
epithelial cell line, GES1 (Supplementary Figure 1A). 
This showed 2-fold increase in FSTL3 mRNA 
(Supplementary Figure 1B) and protein (Supplementary 
Figure 1A) levels. Increased FSTL3 expression 
promoted increased GES1 cell viability (Supplementary 
Figure 1C). Analysis of EdU incorporation showed 30% 
increase in new DNA synthesis in FSTL3-
overexpressing cells compared to control 
(Supplementary Figure 1D). Analysis of GES1 FSTL3-
overexpressing cells revealed 75% increase in colony 
formation compared to control (Supplementary Figure 
1E). To further test inference from our bioinformatics 
studies, we knocked down and overexpressed the 
expression of FSTL3 in gastric cancer cells. It was 
found that the over-expression of FSTL3 promotes cell 
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adhesion and the number of focal adhesion spots 
(Supplementary Figure 2A, 2B). 
 
FSTL3 promotes gastric cancer cell tumorigenicity 
in vivo 
 
We then assessed the contribution of FSTL3 to gastric 
cancer cell tumorigenicity using an in vivo animal model 
(Figure 4). The MGC-803 gastric cancer cell line 
expressing the sh-FSTL3 construct with stable FSTL3 
knockdown was compared to the parental cell line 
(control) for the ability to promote tumor development  
in the immunocompromised Nude mouse model. 
Bioimaging of MC-803-derived tumors in Nude mice 
showed that tumor size was reduced (Figure 4A). Tumors 




Figure 2. Differential gene expression and functional enrichment during FSTL3 overexpression. (A) Volcano map of differentially 
expressed genes under conditions of elevated FSTL3 levels; adjusted P<0.05. (B) The top 10 differentially expressed genes (linked to FSTL3 
overexpression) in gastric cancer disease presented as a gene expression heat map. (C) Gene ontology (GO) term enrichment analysis; 
adjusted P<0.05. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) biochemical pathway enrichment analysis; adjusted P<0.05.  
(E) Protein-protein interaction (PPI) network analysis for 122 differentially expressed genes linked to gastric cancer; minimum required 
interaction score: 0.900. (F) Specific PPI nodes within the full network with MYOCD tool in Cytoscape. 
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knockdown suggested smaller tumor size compared to 
parental MGC-803-derived tumors (Figure 4B). Further 
analysis revealed 50% reduction in tumor weight upon 
FSTL3 knockdown (Figure 4C). There was 30% 
reduction in tumor volume upon FSTL3 knockdown 
(Figure 4C). Hematoxylin-eosin staining of tumor 
sections suggested a more irregular cell shape and 
packing in tumors from the parent cell line MGC-803-
derived tumor compared to FSTL3 knockdown 
conditions (Figure 4D). Analysis of the cell 
proliferation marker, Ki67, showed a much higher 
immunoreactivity for nuclear Ki67 in parent cell line 
MGC-803-derived tumors compared to FSTL3 




Figure 3. FSTL3 overexpression or knockdown modulates gastric cancer cell viability, proliferation and migration. (A) Western 
blot analysis of FSTL3 protein levels in GES1, MGC-803, SGC-7901, BGC-823, HGC-27 and AGS gastric cell lines; blotting for the housekeeping 
protein β-actin was used as a loading control in this experiment. (B) Analysis of relative FSTL3 mRNA levels in GES1, MGC-803, SGC-7901, 
BGC-823, HGC-27 and AGS gastric cell lines using qRT-PCR (see Materials and Methods). (C) Overexpression of FSTL3 in gastric cancer cell line 
SGC-7901 monitored by Western blotting and qRT-PCR. (D) FSTL3 knockdown in gastric cancer cell line MGC-803 monitored by Western 
blotting and qRT-PCR. (E) FSTL3 overexpression (SGC-7901) or knockdown (MGC-803) cell lines were analyzed for cell viability compared to 
controls. (F) FSTL3 overexpression (SGC-7901) or knockdown (MGC-803) cell lines were assayed for cell proliferation using EdU incorporation. 
(G) Wounded cell monolayer assays on FSTL3 overexpression (SGC-7901) or knockdown (MGC-803) cell lines (48h). (H) Transwell cell 
migration assay on FSTL3 overexpression (SGC-7901) or knockdown (MGC-803) cell lines followed by staining of Transwell filters to detect 
migrated cells. (I) FSTL3 knockdown and effects on MGC-803 cell colony formation. Quantification in panels (B–I) were carried out as 
described in Materials and Methods and compared to control cell lines. Error bars indicate +SEM; significance indicated by asterisks, *P<0.05, 
**P<0.01, ***P<0.001; number of experiments, n=3. 
 
www.aging-us.com 20310 AGING 
FSTL3 expression in these tumors using Western 
blotting, and found 70% decrease in FSTL3 mRNA 
levels correlated with decreased FSTL3 protein levels in 
MGC-803 knockdown cells (Figure 4E). Under these 
condition, stable FSTL3 knockdown caused 30% 
decrease in expression of cell proliferation marker, Ki67 
(Figure 4E). 
 
We then assessed the effects on tumor metastasis in vivo 
using tail vein administration of MGC-803 parental line 
or MGC-803/sh-1 cell into Nude mice. After allowing 
tumors to develop and spread systemically, we analyzed 
the frequency of mouse lung tissues for secondary 
tumor metastases. There were both 2 deaths in the 
control group and FSTL3 knockdown group of nude 
mice. Bioluminescence imaging results revealed that 
FSTL3 knockdown significantly reduced incidence in 
the lung of metastatic secondary tumors (Figure 4F, 
4G). The expression levels of FSTL3 thus influences 




Figure 4. FSTL3 expression promotes gastric cancer tumorigenicity in vivo. (A) Bioimaging of MGC-803-derived tumors in the flanks 
of Nude mice. Growth of tumors in Nude mice injected for control MGC-803 cells (NC) or cells expressing shRNA-specific for FSTL3 (sh-FSTL3). 
(B) Excision and viewing of subcutaneous tumors derived from Nude mice injected for control MGC-803 cells (NC) or cells expressing shRNA-
specific for FSTL3 (sh-FSTL3). (C) Analysis of weight or volume of tumors derived from Nude mice injected for control MGC-803 cells (NC) or 
cells expressing shRNA-specific for FSTL3 (sh-FSTL3). (D) Hematoxylin-eosin (upper panels) or Ki67 immunohistochemistry (lower panels) on 
tissue sections from subcutaneous tumors derived from Nude mice injected for control MGC-803 cells (NC) or cells expressing shRNA-specific 
for FSTL3 (sh-FSTL3). (E) Analysis of FSTL3 and Ki67 using Western blotting of tumors from Nude mice injected for control MGC-803 cells (NC) 
or cells expressing shRNA-specific for FSTL3 (sh-FSTL3). Blotting of tumor lysates using antibodies to FSTL3 or Ki67; antibodies to β-actin were 
used to check for protein loading in tumor lysates. (F) Bioluminescence imaging results of the lung metastasis frequency from Nude mice 
injected for control MGC-803 cells (NC) or cells expressing shRNA-specific for FSTL3 (sh-FSTL3). (G) Statistical analysis of luminescence 
intensity. Error bars indicate +SEM; significance indicated by asterisks, *P<0.05, **P<0.01, ***P<0.001; number of experiments, n=3. 
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FSTL3 mRNA is a target of miR-486-5p 
 
To evaluate whether mRNA turnover was a potential 
regulatory mechanism to control FSTL3 protein levels, 
we used StarBase (https://web.archive.org/web/ 
20110222111721/http://starbase.sysu.edu.cn/) to look for 
potential miRNAs that bind to FSTL3. Using this 
approach, we identified an miRNA termed miR-486-5p as 
a potential regulator which binds to a site in the 3’UTR of 
the FSTL3 mRNA (Figure 5A). To assess the correlation 
between miR-486-5p, FSTL3 and cancer status, we used 
the STAD database within TCGA. We found that miR-
486-5p levels were significantly decreased in gastric 
cancer patients compared to controls (Figure 5B). Further 
analysis showed a correlation between decreased miR-
486-5p levels with increased FSTL3 levels (Figure 5C). 
We then examined miR-486-5p levels in normal gastric 
epithelial cells (GES1) vs. gastric cancer cell lines, MGC-
803 and SGC-7901, using qRT-PCR (Figure 5D). There 
was a significant 20-30% decrease in miR-486-5p levels 
in gastric cancer cell lines (MGC-803, SGC-7901) 
compared to normal gastric cells (GES1). 
 
To further verify whether FSTL3 is indeed a target of 
miR-486-5p we constructed a synthetic miR-486-5p 
mimic. Transfection of this miR-486-5p mimic was 
transfected into gastric cancer cell line MGC-803: FSTL3 
expression was decreased 50% (Figure 5E). We also 
made a synthetic miR-486-5p inhibitor, and delivery of 
this into gastric cancer cells caused a 1.5-2-fold rise in 
FSTL3 protein levels; this correlated with a 2.5-fold rise 




Figure 5. FSTL3 mRNA is regulated by miR-486-5p levels. (A) Schematic depiction of the predicted binding site for miR-486-5p in the 
FSTL3 mRNA. (B) Analysis of miR-486-5p levels in gastric cancer tumors vs. normal tissues in the STAD database in TCGA. (C) Correlative 
analysis of miR-486-5p and FSTL3 levels in gastric cancer tumors using the STAD database. (D) Profiling of miR-486-5p levels in normal and 
cancer gastric cancer cell lines using qRT-PCR. (E) Western blotting was used to analyze protein and RNA levels in gastric cancer MGC-803 
cells subjected to transfection with miR-486-5p mimic or miR-486-5p inhibitor. (F) A dual luciferase assay was carried out using transfection 
of luciferase plasmid constructs alongside miR-486-5p mimic or miR-486-5p inhibitor. HEK 293T cells co-transfected with Luc-FSTL3-wt (WT) 
or Luc-FSTL3-mut (MUT) plasmids with synthetic miR-486-5p constructs. Error bars indicate +SEM; significance indicated by asterisks, 
*P<0.05, **P<0.01, ***P<0.001; number of experiments, n=3. 
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also used a dual luciferase reporter assay where the 
luciferase cDNA was fused to either the wild-type 
FSLT3 3’UTR (FSLT3-wt) or a mutant FSLT3 3’UTR 
that was defective for binding miR-486-5p. Co-
transfection of miR-486-5p mimic and luciferase 
FSTL3-wt showed 60% reduction in luciferase activity 
(Figure 5F). In contrast, co-transfection of miR-486-5p 
mimic and luciferase FSTL3-mut showed no effect on 
luciferase activity (Figure 5F). These data suggest that 
miR-486-5p directly regulates FSTL3 mRNA stability 
and/or degradation. 
 
MiR-486-5p specificity for FSTL3 mRNA and effects 
on gastric cancer cell responses 
 
To understand the link between FSTL3 mRNA and 
miR-486-5p, we evaluated whether such potential 
regulation impacts on gastric cancer cell responses. We 
focused on the miR-486-5p inhibitor and its ability to 
modulate FSTL3 knockdown by shRNA (Figure 6). We 
transfected alone or co-transfected the shRNA specific 
for FSTL3 and/or miR-486-5p inhibitor in the MGC-
803 cell line followed by Western blotting (Figure 6A). 
The FSTL3 protein levels were knocked down by sh-
FSTL3, however, this effect could be partially reversed 
by miR-486-5p inhibitor (Figure 6A, 6B). The miR-
486-5p inhibitor caused a substantial 2-fold rise in 
FSTL3 mRNA levels (Figure 6B). The sh-FSTL3 
construct caused 60% knockdown of FSTL3 mRNA 
levels; however, this was partially reversed by miR-
486-5p inhibitor with 2-fold rise in FSTL3 mRNA 
levels (Figure 6B). 
 
We then assessed the effects of targeting miR-486-5p 
on MGC-803 gastric cancer cell responses. The miR-
486-5p inhibitor caused a substantial rise in new 
proliferating cells compared to control (NC) cells, 
shown by EdU staining (Figure 6C). The sh-FSTL3 
construct caused reduced nuclear EdU staining; 
however, this was reversed by miR-486-5p inhibitor 
(Figure 6C). Using the wounded cell monolayer closure 
assay, we demonstrated that control (NC) cells show 
wounded monolayer closure after 24 h (Figure 6D). 
Transfection of miR-486-5p inhibitor caused a dramatic 
increase in wounded monolayer closure; this miR-486-
5p inhibitor caused a partial reversal in the inhibitory 
effects mediated by sh-FSTL3 construct in this assay 
(Figure 6D). Similar conclusions were reached in the 
analysis of cell migration using the Transwell assay 
(Figure 6E). Transfection of miR-486-5p inhibitor 
caused a dramatic increase in MGC-803 cell migration; 
furthermore, miR-486-5p inhibitor and sh-FSTL3 
treatment together caused a partial reversal of the 
inhibitory effects on MGC-803 cell migration caused by 
sh-FSTL3 construct treatment alone (Figure 6D). Such 
findings further support the function role of miR-486-5p 





The follistatin (FST) family of secreted glycoproteins 
are increasingly associated with different types of 
cancers. In a functional analysis of a family member, 
termed FSTL3, we provide evidence that a mechanism 
which directly modulates FSTL3 mRNA levels directly 
impacts on gastric cancer cell responses which 
contribute to cancer development and progression. This 
is based on 4 lines of evidence. First, cancer 
bioinformatics shows a clear association with increased 
FSTL3 expression in gastric cancer patients. 
Furthermore, high FSTL3-expressing gastric cancer 
patients have reduced survival over a 10 yr period. 
Second, modulation of FSTL3 expression in a human-
mouse tumor xenograft model, suggests that higher 
levels of FSTL3 are linked to increased tumor growth 
and spread. Third, modulation of FSTL3 shows a clear 
link with gastric cell responses such as cell viability, 
proliferation and migration. Finally, FSTL3 mRNA is 
regulation by miR-486-5p modulates FSTL3 expression 
and gastric cancer cell-associated responses. 
 
FSTL3 is a secreted glycoprotein encoded by a gene 
located on human chromosome 19q13.3. FSTL3 was 
originally discovered as a rearranged gene locus 
associated with some blood disorders and 
malignancies [12]. The follistatin (FST) family 
members are single-chain monomeric glycoproteins 
which potentially interact with other soluble factors 
and/or membrane receptors [27]. Follistatin can bind 
to members of the TGF-β superfamily (e.g. activin); it 
can also bind FSH and inhibits its biological activity. 
Another family member, FSTL1 is associated with 
reduced levels in prostate cancer; FSTL1 expression 
correlates with inflammatory factors and transforming 
factors [28]. In gastric cancer, it was reported that 
FSTL1 knockdown promotes apoptosis via the STAT6 
signaling pathway [29]. In hepatocellular carcinoma, 
FSTL5 expression inhibits the HCC growth in vitro by 
inducing apoptosis [30]. 
 
miRNA is a single-stranded non-coding RNA (18-25 
nucleotides) endogenously encoded which regulates 
protein translation or mRNA degradation via interaction 
with the 3'or 5' untranslated regions (UTRs) of target 
mRNAs [31]. Many cell biological processes such as 
cell proliferation, growth, differentiation, apoptosis and 
the cell cycle are regulated by a variety of miRNAs 
[32]. miR-486-5p is a recently discovered miRNA 
which displays abnormal expression in colon cancer 
[33], gastric cancer [34], liver cancer [35] and other 
malignant tumors; miR-486-5p levels are linked to 
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Figure 6. Evaluating miR-486-5p specificity for FSTL3 mRNA. (A) Western blotting evaluation of FSTL3 protein levels after transfection 
of sh-FSTL3 and/or miR-486-5p inhibitor into MGC-803 gastric cancer cells. Monitoring β-actin levels was used as an internal control in these 
blots. (B) Western blot results were quantified by using Image J software. Error bars indicate +SEM; significance indicated by asterisks, 
**P<0.01, ***P<0.001; number of experiments, n=3. (C) Transfection of sh-FSTL3 and/or miR-486-5p inhibitor into MGC-803 gastric cancer 
cells and evaluation of cell proliferation using EdU assay (24h). (D) Wounded cell monolayer closure assay after transfection of sh-FSTL3 
and/or miR-486-5p inhibitor followed by imaging at 8 and 24 h post-wounding. (E) The Transwell assay for cell migration after transfection of 
sh-FSTL3 and/or miR-486-5p inhibitor was into MGC-803 cells. Sh-NC construct (shRNA) is a negative control for FSTL3 knockdown. (F) 
Quantified results of EdU, wound healing and transwell migration assays. Sh-NC was analyzed as a control. 
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tumor growth and invasion. In gastric adenocarcinoma, 
miR-486-5p is a potential tumor suppressor. 
Comparison of normal gastric epithelial cells and 
tissues vs. gastric cancer cell lines and tumors, and is 
miR-486-5p is a combinatorial risk factor alongside 
olfactomedin-4 (OLFM4) and fibroblast growth factor 9 
(FGF9). The combination of FGF9 expression alongside 
other genes can inhibit gastric cancer cells proliferation 
and is an independent risk factor for predicting gastric 
cancer patient survival [34, 36]. In this study, we found 
that by combining in silico bioinformatics with cellular 
experiments, miR-486-5p levels were down-regulated in 
gastric cancer cell lines and tumors. This is supported 
by previous studies elsewhere [34]. We further 
delineated the potential site of interaction between miR-
486-5p with the 3’UTR of the FSTL3 mRNA. 
Overexpression of a synthetic miR-486-5p mimic 
causes FSTL3 down-regulation; however, use of a 
synthetic miR-486-5p inhibitor causes a rise in FSTL3 
levels. Finally, miR-486-5p and FSTL3 levels correlate 
negatively in an analysis of gene expression in gastric 
cancer tissues. 
 
What is the functional target of FSTL3? One possibility 
is that FSTL3 binds to a cell surface receptor which 
stimulates autocrine signaling and cellular responses 
linked to cell proliferation and migration. Alternatively, 
as noted for the FST founding family member capacity 
to bind other secreted factors, FSTL3 may sequester 
autoinhibitory factors thus effecting a net autocrine 
stimulatory effect. Our findings provide a new 
framework to better understand gastric cancer 
development and progression and develop new 
therapeutic strategies. However, there are also specific 
limitations of our study. First, the incidence of Asian 
and African patients within the TCGA database is low, 
with skewed view of the molecular events underlying 
cancer processes. Whether FSTL3 is a new diagnostic 
biomarker of gastric cancer requires the collection of 
more unbiased clinical datasets across the global 
population. Next, FSTL3 mRNA may be the target of 
multiple miRNAs, and more work is needed to assess 
such factors. The role of miR-486-5p as a regulator of 
FSTL3 miRNA degradation needs to be checked for its 
ability to target other cellular mRNA species. Our work 
clearly supports a role for FSTL3 in promoting gastric 
cancer cell proliferation and migration; furthermore, 
FSTL3 expression contributes to gastric tumor growth, 
invasion and metastasis. FSTL3 shows promise as a 
new biomarker for gastric cancer diagnosis and is a new 




miRNA: microRNA; 3’-UTR: 3’untranslated region; 
TCGA: The Cancer Genome Atlas; GEO: Gene 
Expression Omnibus; PPI: Protein-protein interaction; 
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Supplementary Figure 1. FSTL3 overexpression promotes GES1 cell viability and proliferation. (A) Overexpression of FSTL3 in 
GES1 cells monitored using Western blotting; monitoring the housekeeping protein β-actin was used as a loading control. (B) Overexpression 
of FSTL3 in GES1 cells monitored using qRT-PCR. (C) Overexpression of FSTL3 in GES1 cells assessed by using the cell viability assay. (D) FSTL3 
overexpression in GES1 cells was assessed for effects on cell proliferation using EdU incorporation assay. Cell proliferation was determined by 
EdU staining. (E) FSTL3 overexpression and effects on MGC-803 cell colony formation. Error bars indicate +SEM; significance indicated by 
asterisks, *P<0.05, **P<0.01, ***P<0.001; number of experiments, n=3. 
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Supplementary Figure 2. FSTL3 overexpression promotes cell adhesion activity and the number of focal adhesion. (A) FSTL3 
overexpression in MGC-803 cells was assessed for effects on cell adhesion ability. The adhesion ability of MGC-803 cells is expressed as an 
adhesion ratio. (B) FSTL3 overexpression and effects on the number of MGC-803 cell adhesion spots. Error bars indicate +SEM; significance 
indicated by asterisks, *P<0.05, **P<0.01, ***P<0.001; number of experiments, n=3. 
